Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates.

Pharmaceutics

Kovar L, Schräpel C, Selzer D, Kohl Y, Bals R, Schwab M, Lehr T.
PMID: 32585880
Pharmaceutics. 2020 Jun 23;12(6). doi: 10.3390/pharmaceutics12060578.

Buprenorphine plays a crucial role in the therapeutic management of pain in adults, adolescents and pediatric subpopulations. However, only few pharmacokinetic studies of buprenorphine in children, particularly neonates, are available as conducting clinical trials in this population is especially...

Cite
Kovar L, Schräpel C, Selzer D, et al. Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. Pharmaceutics. 2020;12(6)doi: 10.3390/pharmaceutics12060578.
Kovar, L., Schräpel, C., Selzer, D., Kohl, Y., Bals, R., Schwab, M., & Lehr, T. (2020). Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. Pharmaceutics, 12(6), . https://doi.org/10.3390/pharmaceutics12060578
Kovar, Lukas, et al. "Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates." Pharmaceutics vol. 12,6 (2020). doi: https://doi.org/10.3390/pharmaceutics12060578
Kovar L, Schräpel C, Selzer D, Kohl Y, Bals R, Schwab M, Lehr T. Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. Pharmaceutics. 2020 Jun 23;12(6). doi: 10.3390/pharmaceutics12060578. PMID: 32585880; PMCID: PMC7355427.
Copy Download .nbib Format: NLM
Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions.

Pharmaceutics

Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T.
PMID: 33322314
Pharmaceutics. 2020 Dec 11;12(12). doi: 10.3390/pharmaceutics12121200.

The beta-blocker metoprolol (the sixth most commonly prescribed drug in the USA in 2017) is subject to considerable drug-gene interaction (DGI) effects caused by genetic variations of the

Cite
Rüdesheim S, Wojtyniak JG, Selzer D, et al. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics. 2020;12(12)doi: 10.3390/pharmaceutics12121200.
Rüdesheim, S., Wojtyniak, J. G., Selzer, D., Hanke, N., Mahfoud, F., Schwab, M., & Lehr, T. (2020). Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics, 12(12), . https://doi.org/10.3390/pharmaceutics12121200
Rüdesheim, Simeon, et al. "Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions." Pharmaceutics vol. 12,12 (2020). doi: https://doi.org/10.3390/pharmaceutics12121200
Rüdesheim S, Wojtyniak JG, Selzer D, Hanke N, Mahfoud F, Schwab M, Lehr T. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics. 2020 Dec 11;12(12). doi: 10.3390/pharmaceutics12121200. PMID: 33322314; PMCID: PMC7763912.
Copy Download .nbib Format: NLM
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease.

Pharmaceutics

Schräpel C, Kovar L, Selzer D, Hofmann U, Tran F, Reinisch W, Schwab M, Lehr T.
PMID: 34575443
Pharmaceutics. 2021 Aug 31;13(9). doi: 10.3390/pharmaceutics13091368.

Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates. Model-informed precision dosing (MIPD) with population pharmacokinetic models could help...

Cite
Schräpel C, Kovar L, Selzer D, et al. External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. Pharmaceutics. 2021;13(9)doi: 10.3390/pharmaceutics13091368.
Schräpel, C., Kovar, L., Selzer, D., Hofmann, U., Tran, F., Reinisch, W., Schwab, M., & Lehr, T. (2021). External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. Pharmaceutics, 13(9), . https://doi.org/10.3390/pharmaceutics13091368
Schräpel, Christina, et al. "External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease." Pharmaceutics vol. 13,9 (2021). doi: https://doi.org/10.3390/pharmaceutics13091368
Schräpel C, Kovar L, Selzer D, Hofmann U, Tran F, Reinisch W, Schwab M, Lehr T. External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease. Pharmaceutics. 2021 Aug 31;13(9). doi: 10.3390/pharmaceutics13091368. PMID: 34575443; PMCID: PMC8468301.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries